Table 1.
Characteristics of patients with nonresected, nonmetastatic (NR‐M0) pancreatic carcinoma, by time periods within younger and elderly age groups
| All patients | Patients younger than 75 y | Patients 75 y and older | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | 2006‐2008 | 2009‐2011 | 2012‐2014 | Chi‐square P‐trend | All | 2006‐2008 | 2009‐2011 | 2012‐2014 | Chi‐square P‐trend | All | 2006‐2008 | 2009‐2011 | 2012‐2014 | Chi‐square P‐trend | |
| N | 5964 (%) | 2052% | 2026% | 1886% | 2872 (%) | 1035% | 965% | 872% | 3092 (%) | 1017% | 1061% | 1014% | |||
| Pathological confirmation | |||||||||||||||
| Confirmed | 2790 (47) | 45 | 46 | 49 | 0.022 | 1874 (65) | 63 | 63 | 71 | <0.001 | 916 (30) | 28 | 30 | 30 | 0.208 |
| Not confirmed | 3174 (53) | 55 | 54 | 51 | 998 (35) | 37 | 37 | 29 | 2176 (70) | 72 | 70 | 70 | |||
| Primary tumor | |||||||||||||||
| Head of pancreas | 4499 (75) | 77 | 76 | 74 | 0.098 | 2057 (72) | 73 | 73 | 68 | 0.014 | 2442 (79) | 80 | 79 | 79 | 0.860 |
| Body or tail | 784 (13) | 12 | 12 | 16 | 464 (16) | 15 | 15 | 18 | 320 (10) | 9.1 | 8.9 | 13 | |||
| Overlapping/NOS | 681 (11) | 11 | 12 | 11 | 351 (12) | 11 | 12 | 14 | 330 (11) | 11 | 12 | 8.3 | |||
| Summary stage | |||||||||||||||
| Localized | 1467 (25) | 26 | 26 | 22 | 0.595 | 352 (12) | 15 | 12 | 9.5 | 0.260 | 1115 (36) | 37 | 39 | 32 | 0.631 |
| Nonlocalized | 3789 (64) | 59 | 64 | 67 | 2287 (80) | 75 | 80 | 84 | 1502 (49) | 43 | 49 | 53 | |||
| Unknown | 708 (12) | 15 | 10 | 11 | 233 (8) | 9.8 | 7.8 | 6.5 | 475 (15) | 20 | 12 | 15 | |||
| TNM stage I‐II‐X | 61 | 43 | 77 | ||||||||||||
| TNM stage III | 39 | 57 | 23 | ||||||||||||
| Chemotherapy (%yes) | 967 (16) | 13 | 17 | 19 | <0.001 | 858 (30) | 23 | 31.5 | 36 | <0.001 | 109 (3.5) | 2.8 | 3.5 | 4.3 | 0.053 |
| Local therapy (%yes)a | 324 (5.4) | 5.5 | 4.2 | 6.7 | 0.121 | 288 (10) | 10 | 7.8 | 13 | 0.074 | 36 (1.2) | 1.0 | 0.9 | 1.6 | 0.212 |
| Deceased within 30 d of diagnosis (%yes) | 739 (12) | 12 | 12 | 13 | 0.275 | 191 (6.7) | 6.5 | 6.3 | 7.2 | 0.529 | 548 (18) | 17 | 18 | 18 | 0.704 |
| Deceased within 90 d of diagnosis (%yes) | 1978 (33) | 33.2 | 32.8 | 33.51 | 0.838 | 697 (24) | 25 | 24 | 24 | 0.938 | 1281 (41) | 42 | 41 | 41 | 0.761 |
| Median OS (95% CI) in mo | 5.1 (4.9‐5.2) | 4.9 (4.6‐5.2) | 5.1 (4.8‐5.5) | 5.1 (4.8‐5.5) | 0.088 b | 6.3 (6.0‐6.6) | 5.9 (5.5‐6.4) | 6.7 (6.0‐7.1) | 6.4 (6.1‐6.7) | 0.052 b | 3.9 (3.7‐4.1) | 3.8 (3.5‐4.2) | 3.9 (3.6‐4.4) | 4.0 (3.6‐4.3) | 0.322 b |
CI, confidence interval; NOS, not otherwise specified; OS, overall survival.
a
For example, conventional radiotherapy, SBRT, RFA, and IRE.
b
Log‐rank test.